HIV-associated nephropathy (HIVAN) was first reported nearly simultaneously by investigators in Miami and New York City in 1984 (1-3). These reports described cohorts of HIV seropositive patients who developed nephrotic syndrome followed rapidly by a progressive chronic kidney disease (CKD). The most common biopsy came to be known as collapsing focal segmental glomerulosclerosis. In the past 20 years since its first reports, there has been an extensive body of research generated on HIVAN including pathogenesis, epidemiology, and treatment. Despite this knowledge, HIVAN became the third leading cause of end stage renal disease (ESRD) in African-Americans aged 20-64 by the end of the 1990s. Yet despite this seeming failure, there are favorable reports of therapy, including highly active antiretroviral therapy (HAART), ACE inhibitors, and steroids. In addition, there has also been an improvement in the prognosis given to patients with HIVAN who require dialysis. There have been numerous excellent reviews on pathogenesis and epidemiology of HIVAN (4, 5) . In this review, we shall focus on the clinical issues surrounding the treatment of HIV seropositive patients with renal disease, including future directions.
Definition HIVAN was first reported in 1984 by separate groups of investigators (1-3) who described a renal syndrome consisting of proteinuria, often in the nephrotic range, and a rapid decline in renal function in patients with AIDS. The natural history of HIVAN is often explosive, progression from diagnosing nephrotic syndrome to the initiation of dialysis occurring over months. On biopsy, the most common histopathologic findings are collapsing FSGS, microcystic dilation of tubules, lymphocytic interstitial infiltrates, and interstitial fibrosis (6, 7) . In fact, demonstrating both collapsing FSGS and microcystic dilation of tubules is pathognomonic for HIVAN; and if found in the absence of known HIV infection should prompt an evaluation for HIV disease.
Epidemiology
In the decade following the initial descriptions of HIVAN, the incidence of ESRD due to HIVAN climbed rapidly (8) . Despite the introduction of HAART in 1995 and a prominent reduction in HIV related deaths since then, the incidence of HIVAN plateaued and has not changed significantly. In 1999 HIVAN became the third leading cause of ESRD in African-Americans aged 20-64 after diabetes and hyper tension. Impor tantly, in the HIV seropositive population HIVAN remains the leading cause of ESRD (9) and thus presumably the leading cause of CKD as well.
Unfortunately, since there are no national databases for CKD as there are for ESRD, the incidence of HIVAN in persons not requiring dialysis is unknown. The incidence of ESRD due to HIVAN reported in the Unites States Renal Data System (USRDS) does not take into account any of the HIV positive patients who have chronic renal insufficiency or proteinuria. But even without knowing the incidence of HIVAN not requiring dialysis, with improved survival of HIV seropositive patients it is expected that the prevalence of HIVAN will increase. In small cohorts, the incidence of HIVAN in a general HIV positive population has been reported to be as low as 1.79% or 3.5% when calculated for just the African-American patients (since all HIVAN cases in this cohort occurred in African-Americans) (10) . Another report of autopsy findings estimated the incidence of HIVAN to be as high as 12.5% (11) . If we extrapolate these prevalence estimates and apply them to the 2001 Center for Disease Control estimate that 140,000 African Americans had AIDS (12) , then in 2001 approximately 5,000 to 17,000 African Americans had HIVAN but did not yet require dialysis. Further, since the prevalence of HIV infection in African Americans continues to increase by aboout 15% per year (12) , the population of patients at greatest risk for developing HIVAN continues to expand. Interstingly, the racial predilection of HIVAN for African-Americans is well described in the literature but remains unexplained.
Prognosis
Before the development of protease inhibitors and the widespread use of HAART, there was no therapeutic intervention available to alter the progression of HIVAN to ESRD. In fact, as reported by Abbott and colleagues (13), of the 375,152 patients started on renal replacement therapy between January 1992 and June 1997, 3653 (0.97%) were coded as HIVAN. Then comparing this group to all other ESRD patients, the authors found a significant survival disadvantage in the HIVAN group. They report a two-year all-cause unadjusted survival of HIVAN patients of 36% vs. 64% in all other patients. A calculated hazards ratio for HIVAN was reported as 5.74 (95% CI, 5.40-6.10). However, this analysis was limited to the USRDS database and hence to those patients started on dialysis. It is fair to assume that many patients were too sick with AIDS to start dialysis or may have opted not to receive dialysis, thereby causing an underestimation of the prevalence.
Since the institution of HAART as the mainstay of HIV therapy in the mid 1990s, there have been reports both concluding a reduction in the incidence of HIVAN (14, 15) and suggesting its continued presence (16, 17) . And although the rapidly increasing prevalence of ESRD due to HIVAN appeared to be arrested in 1995, it has since plateaued with little if any decrease in the following years (9) . Thus the impact of antiretroviral therapy on the natural history of HIVAN remains largely unknown, due in large part to the lack of prospective studies and appropriate national databases.
Treatment
As stated above, there are no prospective randomized controlled studies evaluating treatment efficacy for HIVAN. All published studies to date are either retrospective or lack controls. There has also been no advance beyond the use of HAART, ACE inhibitors, and possibly steroids. Prior to HAART, there were reports of varying success with angiotensin-converting enzyme inhibitors, steroids, zidovudine monotherapy, and cyclosporin (18) (19) (20) (21) (22) (23) . HAART on the other hand has resulted in dramatic long-lasting improvements in renal function (24) . Presently, the recommended treatment of proven HIVAN is HAART. In fact, Ahuja and colleagues (25) recently reported that HAART administered to HIV seropositive patients on hemodialysis improves patient survival. Further, within the small group treated with HAART, those HIV+ patients with HIVAN had a shorter survival than patients with another cause of renal failure.
Acute renal failure and HIV seropositivity
The differential diagnosis of acute renal failure (ARF) in a HIV seropositive individual includes all the well-defined etiologies as well as several specific for HIV. Prerenal causes are common due to diarrhea, vomiting, infections, resulting in increased insensible losses, as well as others. Acute tubular necrosis similarly occurs in HIV seropositive persons. Medication induced ARF is also prevalent in the HIV seropositive population due to the use of nephrotoxic agents such as petamidine, foscarnet, Amphotericin B, aminoglycosides, and other antibiotics. Antiretrovirals themselves are also known to cause ARF (26) . Of these indinavir has been most well described (27, 28) as causing ARF due to crystalluria and stone formation. Newer antiretrovirals are also being implicated in both tubular dysfunction and ARF. Tenofovir disoproxil fumerate, a nucleotide reverse transcriptase inhibitor recently released by the FDA, has a better side effect profile than the related drugs cidofovir and adefovir. Since its release, however, it is clear that tenofovir is more similar than expected to these drugs in that it has been reported to cause both Fanconi syndrome (29) and ARF (30) . An added complexity of HAART in the setting of a reduced GFR comes form the need to adjust the dose of many of the antiretroviral agents. Although easily done, in the setting of a labile glomerular filtration rate (GFR), there is an intuitive risk of either administering too much or too little while dosing for the presumed renal function. Working closely with an infectious disease specialist would be quite an asset and is recommended when changes in HAART are contemplated.
Chronic kidney disease and HIV seropositivity
Although HIVAN is the leading cause of ESRD in HIV seropositive persons, it accounts only for about 40% of cases. Thus the remaining 60% of HIV seropositive patients would have lost kidney function due to other causes (i.e. diabetic nephropathy, hyper tensive nephrosclerosis, etc.). Unfortunately, investigations studying HIV seropositive persons with CKD for improved care are lacking in the literature. In the population of HIV seropositive patients who have not yet progressed to ESRD, complications begin to develop as kidney function deteriorates regardless of etiology. Anemia due to decreased erythropoeitin production develops as the glomerular filtration rate (GFR) drops below 60cc/min. Subsequently, activation of 25-OH vitamin D to 1,25-OH vitamin D decreases and along with phosphorus retention leads to secondary hyperparathyroidism. There is also progression of hypertension, heart disease, atherosclerosis, peripheral vascular disease, and malnutrition.
End stage renal disease and HIV seropositivity
When both HIV disease and ESRD affect a single patient, the clinician has the monumental task of trying to reduce mor tality while being cognizant of drug interactions and dose adjustments to minimize iatrogenic morbidity. However, due to the lack of HIV screening, the prevalence of HIV disease in the ESRD population remains unknown, thus limiting our ability to improve upon survival.
In the early 1990s, the average survival of an HIV seropositive person starting dialysis was only one year (31, 32) . Interestingly, other investigators (33) (34) (35) have reported that in addition to degree of proteinuria and age, the number of infections per month, stage of HIV infection, and CD4 count were predictive of survival. Investigators have reported a further reduction in 1 year survival to 16% in dialysis patients with AIDS compared to 77% in those with HIV disease but without AIDS (36). Ahuja, Borucki, and Grady (25) investigated the impact of HAART on survival of HIV seropositive ESRD patients by conducting a retrospective analysis of 22 HIV seropositive ESRD patients treated with either HAART or either single or double antiretroviral therapy. The HAART-treated patients had a 20% mortality rate after 28 ± 17 months, compared to 57% mortality after 13 ± 10 months in those patients treated with only one or two antiretrovirals. Recently Szczech and colleagues reported from the Adult AIDS Clinical Trial Group Renal Complications Committee (37) . In an analysis of dialysis patients between 1998 and 2001, these authors reported a benefit of HAART on both CD4 count and HIV viral load, although mortality was not reported.
The optimal modality of dialysis has also been a consideration in this population for the obvious concerns of disease transmission and susceptibility of infection, and also due to concerns that hemodialysis may stimulate leukocytes to release cytokines and thus increase viral replication (38) (39) (40) (41) . There have been several investigations of dialysis modalities and survival (42) (43) (44) (45) with conflicting results. In 1995 Bloembergen and colleagues (42) reported a 19% greater mortality risk of patients receiving peritoneal dialysis (PD). Two years later Fenton et al (43) reported a 27% lower risk of mortality for PD patients. Then Vonesh et al (44) found no difference in mortality between PD and hemodialysis (HD). And in 1999, Collins and coworkers (45) found a reduced mortality in PD vs HD over the first 2 years of dialysis. However, it was postulated that as residual renal function was lost in PD patients, the overall mortality became similar to HD patients. Again in 1999, Kimmel et al (46) reported similar survival time between PD and HD patients. And recently Ahuja and colleagues (47) screened the USRDS database and evaluated survival times in patients coded with HIVAN, evaluating 6,053 of 6,166 patients with ESRD and HIVAN between December 1995 and December 1999. Of the 6,053 patients, 88% received hemodialysis and 12% received peritoneal dialysis. Upon adjustment for year of starting dialysis, the authors concluded that there was no survival benefit of either dialysis modality.
Kidney transplantation in the HIV-seropositive ESRD population remains controversial. In most centers across the United States and abroad, HIV infection is considered a contraindication to transplantation. Nonetheless, in abstract form, Murphy and colleagues (48) reported on 23 HIV positive subjects who received a combination of cadaveric and living-related kidney transplants across the United States. Prior to transplant these patients had CD4 counts of > 200 cells/mm 3 and undetectable viral loads on HAART for at least 6 months prior to transplant. They reported a 87% graft survival rate at 378 ± 65.9 days. Viral loads remained undetectable in 91% of patients and CD4 counts remained stable at 497 ± 63 cells/mm 3 . Preliminarily, thus, there is evidence to support kidney transplantation as a viable treatment for HIV-seropositive persons with CKD or ESRD. However, care must be taken with careful planning and a close relationship between transplant surgeon, nephrologist and infectious disease physician due to the potential drug-drug interactions at the level of absorptions, site of actions and biotransformation pathways. Such interactions could not only put at risk the function of the transplanted kidney, but also the suppression of HIV activity. This is an area of clinical medicine that requires further research to delineate safe drug combinations and regimens as well as clinical trials.
CONCLUSIONS
Since the initial description in 1984, HIV associated nephropathy has become a leading cause of chronic kidney disease and end stage renal disease especially in the African-American population. Over this time, advances in our understanding of the pathophysiology have led to the development of numerous therapies. As more HIVseropositive persons live longer, more develop renal disease either from HIV or comorbid states and many ultimately require dialysis.
The complexity of caring for these patients on dialysis has recently received an increased appreciation. This is due not only to the high risk of polypharmacy and drug-drug interactions, but also to the overall worse prognosis that HIV-seropositive persons on dialysis have compared to the general dialysis population. However despite this, there has been little impact on outcome in the past few years. Thus it is critical to further both our basic and clinical understanding of the interplay between HIV disease and kidney disease with the goal to develop tailored therapeutics and improve upon the lives of these individuals.
